Baxdrostat beneficial in uncontrolled or resistant hypertension

IF 44.2 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Nature Reviews Cardiology Pub Date : 2025-09-10 DOI:10.1038/s41569-025-01216-0

Irene Fernández-Ruiz

引用次数: 0

Abstract

In patients with uncontrolled or resistant hypertension, the addition of the aldosterone synthase inhibitor baxdrostat to background antihypertensive therapy reduces seated in-office systolic blood pressure after 12 weeks of treatment, according to findings from the BaxHTN trial presented at the ESC Congress 2025.

查看原文本刊更多论文

巴司他对未控制或顽固性高血压有益

根据在2025年ESC大会上提交的BaxHTN试验的研究结果，对于未控制或顽固性高血压患者，在背景降压治疗中添加醛固酮合成酶抑制剂巴司他可在治疗12周后降低坐位收缩压。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Cardiology 医学-心血管系统

CiteScore

53.10

自引率

0.60%

发文量

143

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cardiology aims to be the go-to source for reviews and commentaries in the scientific and clinical communities it serves. Focused on providing authoritative and accessible articles enriched with clear figures and tables, the journal strives to offer unparalleled service to authors, referees, and readers, maximizing the usefulness and impact of each publication. It covers a broad range of content types, including Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives, catering to practising cardiologists and cardiovascular research scientists. Authored by renowned clinicians, academics, and researchers, the content targets readers in the biological and medical sciences, ensuring accessibility across various disciplines. In-depth Reviews offer up-to-date information, while Consensus Statements provide evidence-based recommendations. Perspectives and News & Views present topical discussions and opinions, and the Research Highlights section filters primary research from cardiovascular and general medical journals. As part of the Nature Reviews portfolio, Nature Reviews Cardiology maintains high standards and a wide reach.